The new guidance also provides that a plan will not lose its grandfathered status if a drug offered by the plan is reclassified in a more expensive tier because a generic alternative becomes available. Under these circumstances, the movement of the name brand drug into a higher cost-sharing tier would not cause the plan to lose its grandfathered status.